Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H17FO4S |
Molecular Weight | 372.41 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\C1=C/C3=CC=C(C=C3)S(C)(=O)=O
InChI
InChIKey=MVGSNCBCUWPVDA-MFOYZWKCSA-N
InChI=1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
Molecular Formula | C20H17FO4S |
Molecular Weight | 372.41 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Exisulind (tentative trade name Aptosyn) is an antineoplastic agent, which was originally developed by Cell Pathways. This drug is an inhibitor of phosphodiesterase (PDE) isozymes: PDE5 and PDE4. Inhibition of PDE5 appears to be pharmacologically relevant, which leads to increase cGMP and activate protein kinase G at doses that induce apoptosis, whereas cyclic AMP levels were not changed. Exisulind has been in phase III clinical trials for the treatment of Non-Small Cell Lung Cancer and for the treatment of polyps in patients who have familial adenomatous polyposis (Colorectal Cancer and Small Intestine Cancer). In addition, this drug was in phase II/III for the treatment of Prostate Cancer, however, there studies have been discontinued.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15230629
Curator's Comment: compounds were originally developed by Cell Pathways, which was acquired by, and integrated into, OSI Pharmaceuticals in June 2003.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1827 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11358813 |
112.0 µM [IC50] | ||
Target ID: CHEMBL2093863 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11358813 |
116.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.85 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10656435 |
400 mg 2 times / day single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EXISULIND plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
18.2 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10656435 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EXISULIND plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
48.1 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10656435 |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EXISULIND plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
48.7 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10656435 |
400 mg 2 times / day single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EXISULIND plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
127 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10656435 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EXISULIND plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
174 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10656435 |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EXISULIND plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.88 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10656435 |
400 mg 2 times / day single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EXISULIND plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
6.03 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10656435 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EXISULIND plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10656435 |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EXISULIND plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
inconclusive [IC50 13.8029 uM] | ||||
inconclusive [IC50 34.6713 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes [IC50 12.6 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/17985343/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/17985343/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/17985343/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/17985343/ |
yes | |||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/17985343/ |
yes | |||
yes | ||||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/17985343/ |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
like | ||||
likely | ||||
likely | ||||
likely | ||||
likely | ||||
likely | ||||
no | ||||
no | ||||
no | ||||
yes [Km 15 uM] | ||||
yes [Km 34.1 uM] | ||||
yes [Km 44.6 uM] | ||||
yes [Km 5.2 uM] |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition of rat colon tumors by sulindac and sulindac sulfone is independent of K-ras (codon 12) mutation. | 2000 Feb |
|
Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. | 2000 Jul 1 |
|
Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels. | 2001 Jun |
|
Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. | 2001 Sep |
|
Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. | 2001 Sep 15 |
|
Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. | 2002 Mar |
|
Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells. | 2003 Oct 15 |
|
Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. | 2003 Sep |
|
Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells. | 2004 Jul 5 |
|
Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells. | 2005 Sep 15 |
|
Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. | 2006 Feb 15 |
|
Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells. | 2006 Jun 1 |
|
Exisulind and guanylyl cyclase C induce distinct antineoplastic signaling mechanisms in human colon cancer cells. | 2006 May |
|
Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase. | 2006 Nov 15 |
|
Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon. | 2007 Apr 1 |
|
Activation of protein kinase G Increases the expression of p21CIP1, p27KIP1, and histidine triad protein 1 through Sp1. | 2008 Jul 1 |
|
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study. | 2008 Sep |
|
15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. | 2009 Jul 15 |
|
Sulindac metabolites induce proteosomal and lysosomal degradation of the epidermal growth factor receptor. | 2010 Apr |
|
Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10. | 2015 Jun 5 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16891869
patients with androgen independent prostate carcinoma: receive weekly docetaxel for 4 weeks, followed by 2 weeks of rest; repeated up to a maximum of 6 cycles. Exisulind 250 mg was given orally twice a day starting on day 8 of the study and taken continuously.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21515355
The effects of arsenic trioxide (ATO) in combination with sulindac (SUL), sulindac sulfide (SS) or sulindac sulfone (SF) on human (Jurkat, HL-60, K562 and HPB-ALL) and mouse (EL-4) leukemic cell lines were investigated. The combination of ATO (1 μM) with SS or SF at concentrations over 50 μM induced considerable cytotoxicity in all cell lines. Normal human lymphocytes exposed for 48 h to the combinations showed smaller decrease in viability. The mitochondrial membrane potential measurements (JC-1 probe) indicated an active involvement of mitochondria in the process. The results did not indicate involvement of an inhibitory effect of the combinations on NF-κB activity in Jurkat, HL-60 and K562 cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sun Dec 18 21:18:07 UTC 2022
by
admin
on
Sun Dec 18 21:18:07 UTC 2022
|
Record UNII |
K619IIG2R9
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/14/1387
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
||
|
NCI_THESAURUS |
C1323
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
||
|
FDA ORPHAN DRUG |
79293
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3219
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
PRIMARY | |||
|
CHEMBL488025
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
PRIMARY | |||
|
64212
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
PRIMARY | |||
|
II-79
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
PRIMARY | |||
|
M5226
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
PRIMARY | Merck Index | ||
|
59864-04-9
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
DB06246
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
PRIMARY | |||
|
5472495
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
PRIMARY | |||
|
C1239
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
PRIMARY | |||
|
59973-80-7
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
PRIMARY | |||
|
7744
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
PRIMARY | |||
|
1642020
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
PRIMARY | |||
|
DTXSID6040246
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
PRIMARY | |||
|
EXISULIND
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
PRIMARY | |||
|
K619IIG2R9
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
PRIMARY | |||
|
C025463
Created by
admin on Sun Dec 18 21:18:08 UTC 2022 , Edited by admin on Sun Dec 18 21:18:08 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|